369 related articles for article (PubMed ID: 27467136)
1. Advances in treatment of metastatic renal cell carcinoma.
Gong J; Gerendash B; Dizman N; Khan A; Pal SK
Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
Glen H
Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
[TBL] [Abstract][Full Text] [Related]
3. Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Jain RK; Gandhi S; George S
Urol Oncol; 2017 Nov; 35(11):640-646. PubMed ID: 28887097
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
O'Reilly A; Larkin J
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):251-262. PubMed ID: 28224821
[TBL] [Abstract][Full Text] [Related]
5. Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.
Bendtsen MAF; Grimm D; Bauer J; Wehland M; Wise P; Magnusson NE; Infanger M; Krüger M
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28796163
[TBL] [Abstract][Full Text] [Related]
6. Emerging growth factor receptor antagonists for the treatment of renal cell carcinoma.
Zahoor H; Rini BI
Expert Opin Emerg Drugs; 2016 Dec; 21(4):431-440. PubMed ID: 27690664
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
Abdelaziz A; Vaishampayan U
Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
[TBL] [Abstract][Full Text] [Related]
9. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy.
Hamieh L; Beck RL; Le VH; Hsieh JJ
Clin Genitourin Cancer; 2020 Aug; 18(4):252-257.e2. PubMed ID: 32291161
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
13. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib for the treatment of kidney cancer.
Študentová H; Vitásková D; Melichar B
Expert Rev Anticancer Ther; 2018 Jun; 18(6):511-518. PubMed ID: 29737893
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
[TBL] [Abstract][Full Text] [Related]
16. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib for the treatment of renal cell carcinoma.
Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.
Grassi P; Verzoni E; Ratta R; Mennitto A; de Braud F; Procopio G
Drug Des Devel Ther; 2016; 10():2167-72. PubMed ID: 27462141
[TBL] [Abstract][Full Text] [Related]
20. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.
Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J
Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
